Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.

The Journal of cell biology - 14 Mar 2005

Paganetti Paolo, Calanca Verena, Galli Carmela, Stefani Muriel, Molinari Maurizio

Abstract excerpt

Endoproteolysis of the beta-amyloid precursor protein (APP) by beta- and gamma-secretases generates the toxic amyloid beta-peptide (Abeta), which accumulates in the brain of Alzheimer's disease (AD) patients. Here, we established a novel approach to regulate production of Abeta based on intracell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Precursor Protein Secretases
Share to Antibodies
Share to Aspartic Acid Endopeptidases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Binding, Competitive

Share to Cell Extracts

Share to Culture Media, Conditioned

Share to Endopeptidases

Share to Fluorescent Antibody Technique, Indirect

Source

Open in PubMed Open full text

Identifiers

PMID: 15767460
DOI: 10.1083/jcb.200410047
PMCID: PMC2171775

Genes

APP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15767460-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.PMID 15767460Read ↗

Targeting tauopathy with engineered tau-degrading intrabodies.Semantic proximity Read ↗

Targeting intracellular tau with a gene-encoded single-chain antibody promotes neuronal homeostasis and ameliorates tau pathologySemantic proximity Read ↗

Intrabody applications in neurological disorders: progress and future prospectsSemantic proximity Read ↗

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodiesSemantic proximity Read ↗

Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disordersSemantic proximity Read ↗

Nanobody Therapeutics in Alzheimer’s Disease: From Molecular Mechanisms to Translational ApproachesSemantic proximity Read ↗

Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.Semantic proximity Read ↗

Attenuating amyloid-beta pathology in mice with in situ programmed astrocytesSemantic proximity Read ↗

Intracellular biology of Alzheimer's disease amyloid beta peptide.Semantic proximity Read ↗

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.Semantic proximity Read ↗

Disruption of amyloid precursor protein ubiquitination selectively increases amyloid β (Aβ) 40 levels via presenilin 2-mediated cleavage.Semantic proximity Read ↗

Antibody against Small Aggregated Peptide Specifically Recognizes Toxic Aβ-42 Oligomers in Alzheimer’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.